Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor

Martin Orban, Julia Riegger, Michael Joner, Tomohisa Tada, Rainer Okrojek, Jörg Hausleiter, Adnan Kastrati, Steffen Massberg, Dirk Sibbing

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Little is known about the antiplatelet action of the thienopyridines, clopidogrel and prasugrel, as well as the non-thienopyridine, ticagrelor, in patients suffering from ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock since systematic comparisons of these antiplatelet agents in this devastating condition are limited so far. This is a report of a patient with STEMI undergoing urgent PCI in cardiogenic shock followed by repeated angioplasty after suffering early stent thrombosis (ST) who showed dual thienopyridine treatment failure of clopidogrel and prasugrel, which was successfully overcome by switching the patient to the non-thienopyridine derivative ticagrelor.

Original languageEnglish
Pages (from-to)395-398
Number of pages4
JournalPlatelets
Volume23
Issue number5
DOIs
StatePublished - Aug 2012

Keywords

  • Antiplatelets
  • Cardiogenic shock
  • Prasugrel
  • STEMI
  • Thienopyridine resistance
  • Ticagrelor

Fingerprint

Dive into the research topics of 'Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor'. Together they form a unique fingerprint.

Cite this